Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28636837 | 0.88 | PKM (0.53) | MAPTRAB9ANPC1KDM4EGAA | |
| SCHEMBL1403615 | 0.83 | CYP2C19 (0.59) | MAPTRAB9ANPC1KDM4EGAA | |
| SCHEMBL30232741 | 0.83 | CYP2C19 (0.59) | MAPTRAB9ANPC1KDM4EGAA | |
| SCHEMBL9369901 | 0.81 | MAPT (0.53) | MAPTRAB9ANPC1KDM4EGAA | |
| SCHEMBL17673994 | 0.80 | CYP2C19 (0.49) | MAPTRAB9ANPC1KDM4EGAA | |
| SCHEMBL13920723 | 0.80 | MAPT (0.49) | MAPTRAB9ANPC1KDM4EGAA | |
| SCHEMBL17674134 | 0.80 | MAPT (0.56) | MAPTRAB9ANPC1KDM4EGAA | |
| SCHEMBL18160680 | 0.80 | CYP2C19 (0.48) | MAPTRAB9ANPC1KDM4EGAA | |
| SCHEMBL28679657 | 0.80 | CYP2C19 (0.48) | MAPTRAB9ANPC1KDM4EGAA | |
| SCHEMBL15956178 | 0.79 | CYP2C19 (0.55) | MAPTRAB9ANPC1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10364300-B2 | Method for producing polydienes and polydiene copolymers with reduced cold flow | BRIDGESTONE CORPORATION (JP) | 2019-07-30 | — | — | US | claimed |
| US-20170247478-A1 | Method For Producing Polydienes And Polydiene Copolymers With Reduced Cold Flow | BRIDGESTONE CORPORATION (JP) | 2017-08-31 | — | — | US | claimed |
| EP-3204429-A1 | METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW | Bridgestone Corporation (JP) | 2017-08-16 | — | — | EP | claimed |
| WO-2016057388-A1 | METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW | BRIDGESTONE CORPORATION (JP) | 2016-04-14 | — | — | WO | claimed |
| US-12606544-B2 | JAK1 selective kinase inhibitor | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2026-04-21 | — | — | US | disclosed |
| EP-3956322-B1 | JAK1 SELECTIVE KINASE INHIBITOR | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2025-05-14 | — | — | EP | disclosed |
| CN-113710664-B | JAK1 selective kinase inhibitors | 迪哲(江苏)医药股份有限公司 | 2024-01-26 | — | — | CN | disclosed |
| US-20220220096-A1 | JAK1 SELECTIVE KINASE INHIBITOR | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2022-07-14 | — | — | US | disclosed |
| EP-3956322-A1 | JAK1 SELECTIVE KINASE INHIBITOR | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2022-02-23 | — | — | EP | disclosed |
| CN-113710664-A | JAK1 selective kinase inhibitors | 迪哲(江苏)医药股份有限公司 | 2021-11-26 | — | — | CN | disclosed |
| WO-2020211839-A1 | JAK1 SELECTIVE KINASE INHIBITOR | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2020-10-22 | — | — | WO | disclosed |
| CN-107567464-B | Process for producing polydienes and polydiene copolymers having reduced cold flow properties | 株式会社普利司通 | 2020-04-14 | — | — | CN | disclosed |
| US-20110319438-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | BLEICHER KONRAD (DE) | 2011-12-29 | — | — | US | disclosed |
| US-20100144762-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | BLEICHER KONRAD | 2010-06-10 | — | — | US | disclosed |
| US-7723538-B2 | enzyme inhibitors of membrane-bound carnitine-dependent palmitoyltransferases (CPTs); inhibit gluconeogenesis and therefore counteract hyperglycemia; 4-(3-Benzenesulfonylamino-benzoylamino)-benzoic acid | HOFFMANN-LA ROCHE INC. (US) | 2010-05-25 | — | — | US | disclosed |
| EP-1891001-B1 | SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | disclosed |
| US-20100105667-A1 | Quinoxaline- and Quinoline-Carboxamide Derivatives | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| US-20050176773-A1 | Antiproliferative 2-(heteroaryl)-aminothiazole compounds and pharmaceutical compositions, and method for their use | AGOURON PHARMACEUTICALS, INC. | 2005-08-11 | — | — | US | disclosed |
| US-20050038078-A1 | Antiproliferative 2-(heteroaryl)-aminothiazole compounds and pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2005-02-17 | — | — | US | disclosed |
| WO-2004014904-A1 | ANTIPROLIFERATIVE 2-(HETEROARYL)-AMINOTHIAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220096-A1 | JAK1 SELECTIVE KINASE INHIBITOR | JAK1, JAK2, JAK3 | MAPT 3488/4885RAB9A 1398/4885NPC1 1828/4885 |
| US-20100105667-A1 | Quinoxaline- and Quinoline-Carboxamide Derivatives | ABL1, NQO2, MAP4K5 | MAPT 2623/4885RAB9A 1249/4885NPC1 2473/4885 |
| US-20050176773-A1 | Antiproliferative 2-(heteroaryl)-aminothiazole compounds and pharmaceutical compositions, and method for their use | CDK2, MKI67, CCNK | MAPT 2032/4885RAB9A 2372/4885NPC1 1609/4885 |
| US-20050038078-A1 | Antiproliferative 2-(heteroaryl)-aminothiazole compounds and pharmaceutical compositions, and methods for their use | CDK2, CCNK, MKI67 | MAPT 2107/4885RAB9A 2367/4885NPC1 1498/4885 |
| US-12606544-B2 | JAK1 selective kinase inhibitor | JAK1, JAK2, JAK3 | MAPT 4828/4885RAB9A 2407/4885NPC1 1897/4885 |
| US-20100144762-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | MAPT 2667/4885RAB9A 4702/4885NPC1 581/4885 |
| US-20110319438-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | MAPT 2667/4885RAB9A 4702/4885NPC1 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.